Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lisaftoclax in Mature B-cell Lymphomas
NCT07459608Phase 2Not yet recruiting
- Sponsor
- Henan Cancer Hospital
- Start
- Jul 2026
- Primary completion
- Jul 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of lisaftoclax in indolent B-cell lymphoma, chronic lymphocytic leukemia (CLL), Waldenström macroglobulinemia (WM), marginal zone lymphoma (MZL), sponsored by Henan Cancer Hospital. Planned start Jul 2026; status: not yet recruiting.
02
Drugs
lisaftoclax
03
Conditions
indolent B-cell lymphomachronic lymphocytic leukemia (CLL)Waldenström macroglobulinemia (WM)marginal zone lymphoma (MZL)
Beyond the preview
Go deeper on NCT07459608.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07459608.